MedTrace Logo

D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)

NCT02651441 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2016-05-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of chemotherapy combined with dendritic activated cytokine-induced killer cell (D-CIK) for non-small cell lung cancer (NSCLC).

Conditions

Interventions

DRUG

Gemcitabine

Gemcitabine 1000mg/m2 IV on day1 and day8, repeat every 3 weeks.

DRUG

Cisplatin

Cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.

BIOLOGICAL

D-CIK

8×10\^9 D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.

Sponsors & Collaborators

  • Affiliated Cancer Hospital & Institute of Guangzhou Medical University

    collaborator OTHER

  • Shenzhen Hornetcorn Bio-technology Company, LTD

    lead INDUSTRY

Principal Investigators

  • Zhi Z Zhang, Professor · Affiliated Tumor Hospital of Guangzhou Medical University immunotherapy center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2019-05-31
Completion
2019-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02651441 on ClinicalTrials.gov